Back to dashboard
All PlansCoverageMedium impact

Biosimilars: Interchangeable Products May Increase Patient Access

EmblemHealth·Rheumatology, Gastroenterology, Dermatology +2 more·Provider News
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

EmblemHealth now allows pharmacists to substitute interchangeable biosimilar products for brand-name biologics, similar to generic drug substitutions. This change aims to increase patient access to biologic medications and reduce costs.

Action Required

Action needed
Billing team should educate providers about interchangeable biosimilars and monitor for potential changes in drug codes when patients receive substituted biosimilar products at the pharmacy. Review FDA resources on biosimilars to understand which products may be interchangeable.

Related policy hubs